Breaking

Medication

1 stories

AllUNIQUEPHARMACEUTICALNOVONORDISKELILILLYAMGENFDAMERCKHEALTHPHARMACEUTICALSTGMCENVIRONMENT CANADAAKSTONPHARMACYTELANGANA DCAIMHDEAMHRAAMBLEPLASTICSURGERYAKSTON BIOSCIENCESTLCFFXNOWLIPFENDRAHSCPREP4ALLMEDSCAPEGSKFRACTYLHEALTHTRUMPRXTELEHEALTHGLENMARKMEDICAREEUROPEAN COMMISSIONHMSACVSCAR EMARKONCOLOGYKETABONPHARMACEUTICALLUPINLEQEMBIASCENSIONSAHPRAKENVUE
Laura Nisenbaum PhD from the Alzheimer’s Drug Discovery Foundation discussing the new at-home lecanemab treatment protocol.
LEQEMBI6d ago

FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment

The FDA has granted approval for a subcutaneous starting dose regimen of lecanemab, known as Leqembi. This regulatory decision allows individuals with early-stage Alzheimer disease to initiate treatment at home through w

← BACK TO ALL HEALTH NEWS